Local medtech companies are stepping up to fight COVID-19 and changing the way they work in the process.

That’s what Spark Therapeutics‘ Kristin Kahle, Ph. D told Technical.ly reporter Paige Gross during an Amplify Philly @ Home fireside chat last week, when the two discussed the role Philadelphia’s medtech community is playing in helping find a cure for COVID-19 and how Kahle’s professional journey has led to her current position.

In her role as immunomonitoring lead at Spark, which last year was acquired by Roche in a $4.8 billion deal (Philly’s biggest-ever VC-backed exit), Kahle and her team study gene therapy for people with genetic disorders.

READ FULL ARTICLE HERE